Breast Cancer Symposium - Enhancing Clinical Care Through Collaboration

BOLERO-2 Examines Everolimus/Exemestane in HR+/HER2- Breast Cancer

According to Dr. Hope S. Rugo, BOLERO-2 results might help generate new hypotheses regarding combinations of novel targeted agents as treatment for hormone receptor-positive/HER2-negative breast cancer. No predictive marker for determining everolimus efficacy was identified by each of the four most frequently altered genes/pathways. However, a greater benefit from everolimus was derived in patients with minimal genetic alterations in PIK3CA/CCND1 or FGFR1/2 genes.